Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Serina Therapeutics Q3 2026 Results: Net Loss of $7.91M, Loss Widens

Serina Therapeutics reported a net loss of $21.2 million for the nine months ended September 30, 2026, as it continues to invest in research and development. The company significantly strengthened its balance sheet during the period, increasing cash and cash equivalents to $19.4 million through private placements and equity facilities.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.10.0
Net income-7.9-4.6
EPS (diluted, $ a share)$-0.31$-0.45

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NYSE: SER. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Serina Therapeutics, Inc.: key numbers

Share price
$1.42Close, Nov 16
Market cap
$37.7M
Shares outstanding
26.57MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Serina Therapeutics, Inc.

All →
4:13 PM ET 8-K
Financial Results

Serina Therapeutics Financial Results

Serina Therapeutics reported third quarter 2026 financial results and provided a clinical update on its SER-252 program for Parkinson's disease. The company has advanced to Cohort 2 of its registrational study following a positive safety review, with topline single-ascending-dose data expected in the first half of 2027.

“We are excited about the achievement of important clinical milestones for SER-252 in Parkinson's disease, advancing from the initial evaluation of our lowest-dose cohort into the next stage of dose escalation. Importantly, the blinded pharmacokinetic observations from Cohort 1 showed the sustained drug exposure SER-252 was designed to achieve, and the independent Safety Monitoring Committee recommended proceeding with continued development.”

Steve Ledger, Chief Executive Officer
5:19 PM ET 8-K
Other 8-K Filing

Serina Therapeutics Other 8-K Filing

Serina Therapeutics filed a Certificate of Elimination with the State of Delaware to remove the Series A Convertible Preferred Stock designation from its charter. All previously issued shares of Series A Preferred Stock have been converted into common stock, and the eliminated shares have returned to the status of authorized but unissued preferred stock.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.